TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ZEPATIER

ELBASVIR
Approved 2016-01-28
Jump to: Indications Approvals Trials Competitors Safety Patents
2
Indications
--
Phase 3 Trials
1
Priority Reviews
10
Years on Market

Details

Status
Discontinued
First Approved
2016-01-28
Routes
ORAL
Dosage Forms
TABLET

Companies

Merck
Active Ingredient: ELBASVIR , GRAZOPREVIR

ZEPATIER Approval History

Loading approval history...

What ZEPATIER Treats

2 FDA approvals

Originally approved for its first indication in 2016 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ZEPATIER FDA Label Details

Pro

ZEPATIER Patents & Exclusivity

Latest Patent: May 2031

Patents (2 active)

US8871759 Expires May 4, 2031
US7973040 Expires Jul 24, 2029
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA208261 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.